PRIMUS LIQUID CONTROL FOR GHB/ALC LEVEL I AND LEVEL II

K992921 · Primus Corp. · LCP · Nov 12, 1999 · Hematology

Device Facts

• Record ID: K992921
• Device Name: PRIMUS LIQUID CONTROL FOR GHB/ALC LEVEL I AND LEVEL II
• Applicant: Primus Corp.
• Product Code: LCP · Hematology
• Decision Date: Nov 12, 1999
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 864.7470
• Device Class: Class 2

Intended Use

Evaluate glycated hemoglobin test accuracy In vitro diagnostic use only

Device Story

Primus Liquid Controls for GHb/A1c (Level I and II) are in vitro diagnostic control materials used to assess the accuracy of glycated hemoglobin testing. These liquid controls are utilized by laboratory personnel to monitor the performance of GHb/A1c assay systems. By comparing the measured values of the controls against expected ranges, clinicians verify the reliability of patient test results. The device serves as a quality control tool to ensure analytical precision and accuracy in clinical laboratory settings, ultimately supporting the validity of diagnostic decisions regarding glycemic control.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Liquid control material for GHb/A1c assays. Formulated as Level I and Level II controls for in vitro diagnostic use. No specific materials, energy sources, or software algorithms described.

Indications for Use

Indicated for in vitro diagnostic use to evaluate the accuracy of glycated hemoglobin (GHb/A1c) testing.

Regulatory Classification

Identification

A glycosylated hemoglobin assay is a device used to measure the glycosylated hemoglobins (A1a , A1b , and A1c ) in a patient's blood by a column chromatographic procedure. Measurement of glycosylated hemoglobin is used to assess the level of control of a patient's diabetes and to determine the proper insulin dosage for a patient. Elevated levels of glycosylated hemoglobin indicate uncontrolled diabetes in a patient.

Submission Summary (Full Text)

{0}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes extending from its head, representing health, services, and people. The eagle is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA".

## NOV 1 2 1999

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Jim Noffsinger, Ph.D. Vice President, Research and Development Primus Corporation P.O. Box 22599 Kansas City, Missouri 64113

Re: K992921

Trade Name: Primus Liquid Control for GHb/A1c Level I and Level II Regulatory Class: II Product Code: LCP Dated: August 26, 1999 Received: August 30, 1999

Dear Dr. Noffsinger:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

K992921 510(k) Number: Device Name: Primus Liquid Controls for GHb/A1c Level I and II Indications For Usc: Evaluate glycated hemoglobin test accuracy In vitro diagnostic use only

Concurrence of CDRH Office of Device Evaluation (ODE)

Kitu E. Makini

(Division Sign-Off)
Division of Clinical Laboratory Devices K992821
510(k) Number

Prescription Use
(Per 21 CFR 801.109)

/

OR

Over-the-Counter Use

(Optional Format 1-2-96)